Grant Krafft, PhD, is a co-founder of Acumen and currently serves as chief scientific adviser. Prior to forming Acumen, Dr. Krafft was research professor of molecular pharmacology and biological chemistry at Northwestern University Medical School, where he and his colleagues discovered Amyloid-beta Derived Dementing Ligands (ADDLs). Dr. Krafft also served as director of research development for the ENH Research Institute. Previously, Dr. Krafft was chief technical officer of Tibotec-Virco, a HIV therapeutics and pharmacogenomics company, and a Volwiler Research Fellow at Abbott Laboratories in its diagnostics and pharmaceutical products divisions.
Dr. Krafft holds a BS in chemistry from Valparaiso University, and a PhD in organic chemistry from the University of Illinois, Urbana-Champaign. He is an author on more than 75 scientific papers and a co-inventor on more than 20 issued and pending patents.